EYE-GO A/S - CVR: 36957670

2023, DKK

25.06.2024

Bruttoresultat

-1.854'

Primær drift

-3.250'

Årets resultat

-1.088'

Aktiver

27.079'

Kortfristede aktiver

7.702'

Egenkapital

19.424'

Afkastningsgrad

-12 %

Soliditetsgrad

72 %

Likviditetsgrad

471 %

Resultat

25.06.2024

Årsrapport	2023 25.06.2024	2022 15.06.2023	2021 23.05.2022	2020 02.07.2021	2019 22.05.2020	2018 31.05.2019	2017 19.06.2018	2015 30.06.2017
Nettoomsætning
Bruttoresultat	-1.853.676	-729.160	-4.487.992	-3.187.784	-3.028.217	-7.855.430	-5.301.699	-2.358.631
Resultat af primær drift	-3.250.432	-2.005.735	-6.952.571	-4.420.975	-5.098.614	-10.803.285	-10.790.711	-2.738.631
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	31.108	31.932	31.282	18.768	69.423	0	0	0
Finansieringsomkostninger	-127.826	-310.884	-279.878	-67.224	0	0	0	0
Andre finansielle omkostninger	0	0	0	0	-38.846	-12.562	-111.159	-37
Resultat før skat	-3.347.150	-2.284.687	-7.201.167	-4.469.431	-5.068.037	-10.815.847	-10.901.870	-2.738.668
Resultat	-1.088.011	-644.647	-5.654.295	-3.492.115	-3.956.201	-7.043.685	-10.901.870	-2.738.668
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

25.06.2024

Årsrapport	2023 25.06.2024	2022 15.06.2023	2021 23.05.2022	2020 02.07.2021	2019 22.05.2020	2018 31.05.2019	2017 19.06.2018	2015 30.06.2017
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	3.997.503	2.027.071	2.625.858	2.528.308	4.321.071	5.323.860	1.052.849	115.068
Likvider	3.704.241	9.048.168	228.233	6.429.715	760.395	1.201.436	11.958.506	129.377
Kortfristede aktiver	7.701.744	11.075.239	2.854.091	8.958.023	0	0	0	0
Immaterielle aktiver og goodwill	17.723.544	7.454.728	0	0	0	0	0	4.520.000
Finansielle anlægsaktiver	50.547	50.547	50.547	50.547	50.547	50.547	50.547	0
Materielle aktiver	1.603.273	2.073.454	7.615	7.615	7.615	22.213	15.136	0
Langfristede aktiver	19.377.364	9.578.729	58.162	58.162	58.162	72.760	65.683	4.520.000
Aktiver	27.079.108	20.653.968	2.912.253	9.016.185	5.139.628	6.598.056	13.077.038	4.764.445

Aktiver

25.06.2024

Passiver

25.06.2024

Årsrapport	2023 25.06.2024	2022 15.06.2023	2021 23.05.2022	2020 02.07.2021	2019 22.05.2020	2018 31.05.2019	2017 19.06.2018	2015 30.06.2017
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	19.423.736	4.706.358	-2.849.044	2.805.251	4.630.699	5.586.902	12.630.587	4.721.352
Hensatte forpligtelser	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld		5.546.391	5.264.818	5.104.900	28.815	0	0	0
Leverandører af varer og tjenesteydelser	1.303.551	262.686	109.999	764.174	304.000	531.197	90.384	38.093
Kortfristede forpligtelser	1.633.808	10.401.219	496.479	1.106.034	480.114	1.011.154	446.451	0
Gældsforpligtelser	7.655.372	15.947.610	5.761.297	6.210.934	0	0	0	0
Forpligtelser	7.655.372	15.947.610	5.761.297	6.210.934	0	0	0	0
Passiver	27.079.108	20.653.968	2.912.253	9.016.185	5.139.628	6.598.056	13.077.038	4.764.445

Passiver

25.06.2024

Nøgletal

25.06.2024

Årsrapport	2023 25.06.2024	2022 15.06.2023	2021 23.05.2022	2020 02.07.2021	2019 22.05.2020	2018 31.05.2019	2017 19.06.2018	2015 30.06.2017
Afkastningsgrad	-12,0 %	-9,7 %	-238,7 %	-49,0 %	-99,2 %	-163,7 %	-82,5 %	-57,5 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-5,6 %	-13,7 %	198,5 %	-124,5 %	-85,4 %	-126,1 %	-86,3 %	-58,0 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-2.542,9 %	-645,2 %	-2.484,1 %	-6.576,5 %	Na.	Na.	Na.	Na.
Soliditestgrad	71,7 %	22,8 %	-97,8 %	31,1 %	90,1 %	84,7 %	96,6 %	99,1 %
Likviditetsgrad	471,4 %	106,5 %	574,9 %	809,9 %	Na.	Na.	Na.	Na.

Resultat

25.06.2024

Gæld

25.06.2024

Årsrapport

25.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 25.06.2024)

Information om virksomhedens regnskabsklasse:The annual report of EYE-GO A/S for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

25.06.2024

Dato for ledelsens godkendelse af årsrapporten:2024-06-25

Oplysning om usædvanlige forhold:Management is responsible for ensuring that the Company’s capital resources are sound at any timeand that sufficient liquidity is available to meet the Company's current and future liabilities as they falldue. The company has raised additional capital in June 2024 to support the company’s growth strategyand expect to continuously raise the necessary capital to support the company's growth strategy. Based on the above, Management is of the opinion that the Company has sufficient capital resourcesfor the coming year, and accordingly, presents the annual report on a going concern basis.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of EYE-GO A/S for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:EYE-GO develops disruptive eye care technology that improves the quality of life of people around the world suffering from severe and chronic eye conditions. Revolutionizing the existing eye drop bottle market, the MistGo® product is a novel ocular drug delivery system that is the first viable and truly replacement of the eye drop bottle. MistGo® works by micro-dosing a thin mist into the eye and is part of the next generation delivery systems capable of administering micro-doses for preservative-free liquids. MistGo® is the only system effectively removing all the well-known negative effects and barriers from eye-drop bottles. Patients receive the optimal dose with precise installation every time, minimizing systemic exposure. The product has an eye interface avoiding contamination and ensuring that no parts of the product touch the ocular surface. The technology behind transforms the 6 µL into a precisely targeted mist that is patented in the USA, Europe, and Japan. In 2023 we have finetuned the MistGo® product and made several tests of specific “real-life” customer formulations. These tests have confirmed that MistGo® has a wide performance window regarding viscosity, and the system døs not clog even with sticky formulations. We have delivered MistGo® to clinical studies and we are in the process of developing the first production line. Our business model is to license to pharma companies against milestone payments and generate recurring revenue from long-term supply agreements. EYE-GO targets pharma companies with prescription (Rx) medicine for treatment of chronic eye diseases. The primary segments are glaucoma (a $3. 2B US market) and dry eye disease (“DED”, a $1. 5B US market). Secondary segments are presbyopia (with expected double digit $B revenue within 5-10 years) and myopia. MistGo® is for young companies (new innovative delivery system for new innovative drugs) as well as established companies (life-cycle extension of current drugs).